Tumor-specific surface marker-independent targeting of tumors through nanotechnology and bioorthogonal glycochemistry.

J Clin Invest · 2025 · PMC12043094 · PMID 40067370

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although statistical analysis did not reveal a significant difference between the anti–PD-1 plus TRACER and the anti–PD-1 plus anti–4-1BB treatments, the data showed a trend toward increased CD8 + T cells in the TRACER group.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.